Indivior PLC (FRA:2IVB)

€ 9.8 0.2 (2.08%) Market Cap: 1.21 Bil Enterprise Value: 1.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 63/100

Q3 2024 Indivior PLC Earnings Call Transcript
Oct 24, 2024

€7.95 (-1.24%)

Earnings
Preliminary Q3 2024 Indivior PLC Earnings Call Transcript
Oct 10, 2024

€8.7 (-1.69%)

Earnings
Half Year 2024 Indivior PLC Earnings Call Transcript
Jul 25, 2024

€9.8 (-1.01%)

Earnings
Q1 2024 Indivior PLC Earnings Call Transcript
Apr 25, 2024

€16.8 (-5.62%)

Earnings
Full Year 2023 Indivior PLC Earnings Presentation Transcript
Feb 22, 2024
Indivior PLC Fireside Chat Hosted by Jefferies Transcript
Nov 21, 2023
Q3 2023 Indivior PLC Earnings Presentation Transcript
Nov 09, 2023
Indivior PLC at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Half Year 2023 Indivior PLC Earnings Call Transcript
Jul 27, 2023

€21.65 (-0.69%)

Earnings
Indivior PLC at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Indivior PLC at Bank of America Global Healthcare Conference Transcript
May 11, 2023
Q1 2023 Indivior PLC Earnings Call Transcript
Apr 27, 2023

€16.5 (+0.12%)

Earnings
Full Year 2022 Indivior PLC Earnings Call Transcript
Feb 16, 2023

€18.35 (-16.36%)

Earnings
Indivior PLC Capital Markets Day Transcript
Dec 07, 2022
Indivior PLC to Acquire Opiant Pharmaceuticals Inc Call Transcript
Nov 14, 2022
Q3 2022 Indivior PLC Earnings Call Transcript
Oct 27, 2022

€18.49 (+1.04%)

Earnings
Indivior PLC at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Sep 16, 2022
Indivior PLC at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Half Year 2022 Indivior PLC Earnings Call Transcript
Jul 28, 2022

€18.13 (+0.11%)

Earnings
Q1 2022 Indivior PLC Earnings Call Transcript
Apr 28, 2022

€19.36 (+0.41%)

Earnings
Full Year 2021 Indivior PLC Earnings Call Transcript
Feb 16, 2022

€13.44 (+0.52%)

Earnings
Q3 2021 Indivior PLC Earnings Call Transcript
Oct 28, 2021

€14.16 (-1.80%)

Earnings
Indivior PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
Half Year 2021 Indivior PLC Earnings Call Transcript
Jul 29, 2021

€8.6 (-0.64%)

Earnings
Q1 2021 Indivior PLC Earnings Call Transcript
Apr 29, 2021

€8.5 (+4.74%)

Earnings
Full Year 2020 Indivior PLC Earnings Call Transcript
Feb 18, 2021

€8.44 (+4.71%)

Earnings
Q3 2020 Indivior PLC Earnings Call Transcript
Oct 29, 2020

€5.81 (+0.87%)

Earnings
Half Year 2020 Indivior PLC Earnings Call Transcript
Jul 30, 2020

€7.75 (+2.72%)

Earnings
Q1 2020 Indivior PLC Earnings Call Transcript
May 14, 2020

€2.66 (-2.92%)

Earnings
Full Year 2019 Indivior PLC Earnings Call Transcript
Feb 13, 2020

€2.17 (-25.53%)

Earnings
Q3 2019 Indivior PLC Earnings Call Transcript
Oct 31, 2019

€2.62 (+6.20%)

Earnings
Half Year 2019 Indivior PLC Earnings Call Transcript
Jul 31, 2019

€2.96 (-0.64%)

Earnings
Q1 2019 Indivior PLC Earnings Call Transcript
May 02, 2019

€2.13 (-2.34%)

Earnings
Full Year 2018 Indivior PLC Earnings Call Transcript
Feb 14, 2019

€6.33 (+0.16%)

Earnings

Full Year 2020 Indivior PLC Earnings Call Transcript

Feb 18, 2021 / 12:00PM GMT

Release Date Price: €8.44 (+4.71%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Indivior PLC Full Year Results 2020 Conference Call. (Operator Instructions) I must advise you that this conference is being recorded today, Thursday, 18th of February 2021.

I would now like to hand the conference over to first speaker today, Mark Crossley. Thank you. Please go ahead.

Mark Crossley

Indivior PLC - CEO & Executive Director

Good morning, and good afternoon, everyone. Thank you for joining us to discuss our 2020 results and outlook. I'm joined by Ryan Preblick, our Chief Financial Officer; Christian Heidbreder, our Chief Scientific Officer; and by [Jon Wasserman], our interim External Chief Legal Officer.

We'll take the forward-looking statements as read and move to the agenda for today's discussion. I'll start with an overview of the 2020 results and then detail our strategy for which our #1 priority is realizing the full potential of SUBLOCADE on behalf of patients and stakeholders. Christian will then highlight R&D accomplishments and the progress we

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.